TROP-2
44 programs · 43 companies
Programs
44
Companies
43
Active Trials
28
Targeting TROP-2
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | LNWM | |
| NVS-8902 | Novartis | Preclinical | Melanoma | |
| Zanumavacamten | GSK | Phase 2/3 | MDSADHD | |
| ION-1378 | Ionis | NDA/BLA | CSU | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | MDD | |
| ILM-4317 | Illumina | NDA/BLA | SCD | |
| GPC-2382 | Structure Ther | Preclinical | Wet AMD | |
| 450-8195 | Astellas | NDA/BLA | MSBCC | |
| Talafutibatinib | UCB | Phase 1/2 | CF | |
| Pexazanubrutinib | Opthea | Preclinical | MDSTTR Amyloidosis | |
| GUS-IIT-176 | Gustave Roussy | Phase 2/3 | FL | |
| UCL-IIT-777 | UCLA Health | Preclinical | Crohn's | |
| DUK-IIT-253 | Duke Cancer Institute | Phase 1 | DLBCL | |
| CER-4594 | Cerevel (AbbVie) | Phase 3 | RACeliac | |
| ABL-1749 | Ablynx (Sanofi) | Phase 1 | ALL | |
| Sovalucimab | EQRx | NDA/BLA | CholangiocarcinomaDravet | |
| QUO-8015 | Quotient Ther | Phase 1 | GISTCRC | |
| GEN-718 | GenEdit | Phase 1/2 | MDS | |
| IPS-9466 | Century | NDA/BLA | FLPV | |
| Terazasiran | Selecta Bio | Phase 2 | DravetFTD | |
| GRT-6331 | Gritstone | NDA/BLA | MigraineThymoma | |
| RAP-8975 | RAPT Therapeutics | Phase 2 | FSGSDMD | |
| Polatuximab | Processa Pharma | Phase 1/2 | Pancreatic CaThymoma | |
| NUR-9873 | Nuo Therapeutics | Phase 3 | Crohn'sAS | |
| Suramavacamten | ProMIS Neurosciences | Phase 1 | UCPNH | |
| Fixafotisoran | Spire Biotech | Phase 2/3 | PAH | |
| CLO-2738 | Clovis Oncology | NDA/BLA | Ovarian Ca | |
| NUW-6701 | Nuwellis (fka CHF Sol) | Approved | Urothelial CaProstate Ca | |
| 699-6202 | Genor BioPharma | Phase 1/2 | Heart FailureT2D | |
| Capibrutinib | Aimmune (Nestle) | Approved | ObesityPAH | |
| ENC-4310 | Encoded Ther | Phase 1/2 | PompeCholangiocarcinoma | |
| FRE-IIT-416 | Fred Hutch | Phase 2 | Hemophilia A | |
| Datotuximab | Sensei Bio | Phase 1/2 | SCLCAS | |
| Bemasacituzumab | Taiho Pharma | Phase 1/2 | Hemophilia AOvarian Ca | |
| FER-2115 | Ferring Pharma | Phase 3 | IPFPNH | |
| Pemizumab | Lundbeck | Phase 1 | UCMM | |
| Semazanubrutinib | Newron Pharma | Phase 3 | Parkinson'sCervical Ca | |
| Pexainavolisib | Servier | Phase 3 | MG | |
| Talafutibatinib | Alkem Labs | Phase 3 | PompeADPKD | |
| INS-IIT-499 | Institut Curie | Preclinical | Wet AMD | |
| ASA-IIT-613 | Asan Medical Center | Preclinical | PBC | |
| ROY-IIT-943 | Royal Marsden | Phase 1/2 | Atopic Derm | |
| NAT-IIT-496 | Natl Taiwan Univ Hosp | NDA/BLA | SLE | |
| ZYM-3350 | Zymergen (Ginkgo) | Phase 2/3 | DMD |